Grant Zeng
Grant Zeng
Send Message
Grant Zeng
Stop FollowingGrant Zeng
View as an RSS Feed
-
Bio-Path: Another Overlooked Biotech Company In The Space Of RNA Therapeutics
- Tekmira's TKM-PLK1 Is Promising For Solid Tumors
- Atossa Genetics: Room For Further Price Appreciation
-
Tekmira: An Undervalued Pioneer In The Field Of RNAi Therapeutics
- A Great Move For Galena Biopharma
- NeoGenomics: Poised To Grow Further In 2013 And Beyond
- Galena Shares Are Attractive
- The Next 3 Big Things For ImmunoCellular Therapeutics
- Plenty More Upside In NeoGenomics Shares
- Life Science Research Services Industry Needs Better Technologies
- Why ImmunoCellular Therapeutics Is Different
- Neogenomics Is A Solid Bet In Medical Diagnostics
- Galena Biopharma: An Emerging Biotech Company With Promising Cancer Vaccines
- CytRx Continues To Make Progress To Advance Its Pipeline
- What Can We Expect From CytRx In 2012?
